The Mind-Numbing Way FDA Uncovers Data Integrity Lapses
This article was originally published in The Gold Sheet
Executive Summary
An FDA official encourages industry to use this method to audit supply chains for data integrity – even though it can be mind-numbingly tedious.
You may also be interested in...
Top Stories of 2014
Readers of “The Gold Sheet” focused more on articles about data integrity than any other topic last year, which is a big reason why data integrity was the No. 1 story of 2014. A number of other highly read articles last year focused on additional topics that were also among the top stories in pharmaceutical manufacturing quality last year.
Ranbaxy Whistleblower’s New Mission: How to Detect Fraud from Afar
A decade ago, Dinesh Thakur was able to perceive data integrity issues at Ranbaxy because of his unique position in the company. Today, he’s working to help pharmaceutical companies monitor their global manufacturing networks to detect such issues wherever they might occur.
Transparency Looms Large In US FDA’s Next-Pandemic Legislative Agenda
Agency’s proposals for pandemic preparedness reauthorization would build on CARES Act provisions to gain greater visibility into global pharmaceutical supply chains, while also seeking deeper understanding of manufacturing quality management activities. Also included in FY 2024 budget request: long-sought drug destruction and drug recall authorities.